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prognosis after resection of lung cancer: a
systematic review and a meta-analysis
Haixing Luan1†, Feng Ye2†, Lupeng Wu2, Yanming Zhou2* and Jie Jiang3*Abstract
Background: It is speculated that blood transfusion may induce adverse consequences after cancer surgery due to
immunosuppression. This study was intended to assess the impact of perioperative blood transfusion on the
prognosis of patients who underwent lung cancer resection.
Methods: Eligible studies were identified through a computerized literature search. The pooled relative risk ratio
(RR) with 95% confidence interval (CI) was calculated using Review Manager 5.1 Software.
Results: Eighteen studies with a total of 5915 participants were included for this meta-analysis. Pooled analysis
showed that perioperative blood transfusion was associated with worse overall survival (RR: 1.25, 95% CI: 1.13-1.38;
P <0.001) and recurrence-free survival (RR: 1.42, 95% CI: 1.20-1.67; P <0.001) in patients with resected lung cancer.
Conclusions: Perioperative blood transfusion appears be associated with a worse prognosis in patients undergoing
lung cancer resection. These data highlight the importance of minimizing blood transfusion during surgery.
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Lung cancer is one of the most common cancers world-
wide. Surgical resection is the most effective and poten-
tially curative therapeutic option for this disease. Despite
improvements in surgical and anesthetic techniques, a
great number of patients need perioperative blood trans-
fusions. The immunosuppression from blood products
has led to concerns about its effects on the postoperative
outcome of surgical oncology patients [1]. Some reports
suggested that perioperative blood transfusion was asso-
ciated with worse long-term oncological outcomes after
surgery for lung cancer [2-5], but other studies failed to
find such an association [6-9].
In the light of these conflicting findings, we performed
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undergoing lung cancer resection.
Methods
The study was conducted following the Preferred
Reporting Items for Systematic Reviews and Meta- Ana-
lyses (PRISMA) [10].
Literature search
A computerized search of the literature was performed by
searching Medline, EMBASE, OVID, Cochrane database,
and China National Knowledge Infrastructure from the
time of inception to December 2013. The following med-
ical subject heading terms were used: “lung cancer,” “blood
transfusion,” “prognosis,” and “survival”. Only studies on
humans and in the Chinese and English languages were
eligible for inclusion. Reference lists of all identified arti-
cles were manually searched for additional studies.
Inclusion and exclusion criteria
Inclusion criteria for primary studies were as follows: (i)
the correlation between perioperative allogenenic bloodd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cancer resection; and (ii) data available on overall sur-
vival (OS) or recurrence-free survival (RFS) with a me-
dian follow-up of at least 24 months. For duplicate
publications reported by the same authors, either the
one of higher quality or the most recent publication
was selected. Abstracts, letters, editorials, expert opin-
ions and reviews without original data were excluded
from analysis.
Data extraction
Two reviewers (LW and HL) independently extracted
the following parameters from each study: first author,
year of publication, country of origin, study population
characteristics, study design, inclusion and exclusion
criteria, numbers of participants, relative risk ratio (RR)
or hazard ratio (HR) with 95% confidence interval (CI)
for OS and RFS. All relevant texts, tables and figures
were reviewed for data extraction. If additional data
were needed, the authors were contacted to provide full
details.
The quality of each included study was assessed using
the Newcastle-Ottawa Scale consisting of three factors:
patient selection, comparability of the study groups, and
outcome assessment [11]. Studies achieving 6 or more
stars were considered to be of higher quality.
Outcome measurement
The primary outcomes of this study were OS and RFS.
Statistical analysis and synthesis
The RR with 95% CI was used to evaluate the associ-
ation between perioperative blood transfusions and RFS
or OS. To do this, the HR was directly considered as
RR. DerSimonian-Laird random-effect model was used
to calculate the overall effect estimates. The RR was
transformed to a natural log scale and then calculated
for standard errors (SEs). Where HR was not reported,
published data and figures from original papers were
used to calculate the HR according to the methods de-
scribed by Parmar et al. [12]. Heterogeneity across stud-
ies was evaluated with I2 statistics, with values up to
25%, 25%–50%, and above 50% indicating low, moderate,
and high levels of heterogeneity. The RR was calculated
by a random-effects model when the P value was less
than 0.1. Otherwise, a fixed-effects model was used.
Examination of publication bias was performed using a
funnel plot based on the primary outcome. Sensitivity
analyses were carried out by using the following sub-
groups: (i) studies of high quality; (ii) studies of patients
with stage I disease; and (iii) studies containing more
than 200 patients. All analyses were performed using
the statistical software Review Manager version 5.1 (The
Cochrane Collaboration, Software Update, Oxford).Results
Eligible studies
We identified 647 potentially relevant records. After ex-
cluding studies that did not fulfill our inclusion criteria,
18 studies with a total of 5915 participants were in-
cluded in the final meta-analysis [2,3,5-9,13-23]. The
main features of the included studies are summarized in
Table 1. Of these studies, eight studies were conducted
in the USA [2,3,6-8,13,22,23], two in Italy [6,17], one in
Finland [9], one in Poland [15], one in the United
Kingdom [16], one in Spain [18], one in China [19], one in
France [20], and one in Greece [21]. The number of pa-
tients ranged from 105 to 636 in each study. The transfu-
sion rate in these reports ranged from 9.4 to 55.4%.
There was 100% agreement between the two reviewers.
Primary outcomes
Data on OS were available from 14 studies. Univariate
analysis alone was done in 2 [6,18] of the 14 studies.
Multivariate analysis was done in the remaining 12 series
[3,8,9,13-17,20-23]. In one study [15], the authors stated
that there was no significant impact of transfusion in the
multivariate analysis, but the statistic necessary for
meta-analysis (RR, CI) was not reported; we therefore
extracted the survival data from the Kaplan-Meier curve.
The pooled data indicated that perioperative blood
transfusion was associated with a worse OS (RR: 1.25,
95% CI: 1.13-1.38; P < 0.001) (Figure 1) in patients with
resected lung cancer. As the test for heterogeneity was
significant (I2 = 60%, P =0.002), a random-effects model
was used to calculate the RR. Additional analyses in
which the RR of the multivariate Cox model was pooled
did not change the results significantly (RR: 1.27, 95%
CI: 1.12-1.43; P < 0.001; I2 = 61%, P =0.004).
Data on DFS were available from10 studies. Univariate
analysis alone was done in 1 [6] of the 10 studies. Multi-
variate analysis was done in the remaining 9 series
[2,5-8,13,14,19,22,23]. In two studies [5,19], the authors
stated that transfusion was an independent predictor of
poor RFS, but the statistic necessary for meta-analysis
(RR, CI) was not reported; we therefore extracted the
survival data from the Kaplan-Meier curve. The pooled
data indicated that perioperative blood transfusions was
associated with a worse DFS (RR: 1.42, 95% CI: 1.20-
1.67; P <0.001), with significantly heterogeneity between
studies (I2 = 51%, P = 0.03) (Figure 2). Additional ana-
lyses in which the RR of the multivariate Cox model was
pooled did not change the results significantly (RR: 1.64,
95% CI: 1.37-1.1.96; P <0.001; I2 = 0%, P =0.58).
Sensitivity analysis
As Table 2 shows, the results derived from three sub-
groups were all consistent with those derived from over-
all meta-analysis.
Table 1 Summary of studies included in the meta-analysis
Reference (Year) EI (Country) FD (MM)
(No. of lost)
Group No. of patients (M/F) Age, years PHB, g/dl Pathology
Aa/Sc/Lc/Ot
TS I/II/II/IV OT Pr/Pn Quality score
Tartter [2] (1984) 1966–1980 (USA) 24 Transfused 92 (−) – – – All stage I – 4
(−) Non-transfused 73 (−) – – – All stage I –
Hyman [3] (1985) 1971–1979 (USA) – Transfused 33 (25/8) 59.5 ± 8 – 9/21/3/0 27/6/0/0 22/11 5
(−) Non-transfused 72 (58/14) 62.4 ± 7.1 – 20/38/11/3 67/5/0/0 55/17
Pastorino [6] (1986) 1974–1979 (Italy) – Transfused 157 (147/10) > 60, n = 75 – 53/79/25/0 All stage I 113/44 6
(−) Non-transfused 126 (117/9) > 60, n = 64 – 49/59/18 All stage I 105/21
Keller [7] (1988) 1974–1981 (USA) (−) Transfused 144 (91/53) ≥ 65.1, n = 73 – – 119/25/0/0 127/17 5
– Non-transfused 208 (149/59) ≥ 65.1, n = 65 – – 186/22/0/0 201/7
Little [5] (1990) 1977–1986 (USA) 47 Transfused 58 (32/26) 61.3 ± 8.8 – 26/25/7/0 All stage I 48/10 5
(0) Non-transfused 59 (28/31) 60.1 ± 9.6 – 37/16/6/0 All stage I 51/8
Pena [8] (1992) 1980–1984 (USA) – Transfused 30 (24/6) 66.1 ± 7.6 12.8 ± 1.9 10/15/3/2 23/7/0/0 22/8 6
(−) Non-transfused 97 (78/19) 62.0 ± 8.0 14.2 ± 1.3 41/41/12/3 75/22/0/0 71/26
Piantadosi [13] (1994) 1974–1981 (USA) 43.2 Transfused 169 (−) – – – – – 6
(−) Non-transfused 161 (−) – – – – –
Rainio [9] (1996) 1978–1980 (Finland) – Transfused 95 (88/7) – – – 60/8/27/0 – 5
(−) Non-transfused 113 (102/11) – – – 83/10/20 –
Nosotti [14] (2003) 1995–2000 (Italy) 34 Transfused 69 (52/17) 65.6 ± 9.4 12.5 ± 1.2 39/28/2/0 All stage I – 6
(38) Non-transfused 212 (153/59) 64.5 ± 9.5 13.3 ± 3.1 139/66/7/0 All stage I –
Rzyman [15] (2003) 1993–1997 (Poland) 46 Transfused 185 (155/30) 59.5 ≤12, 25% 51/113/19/2 62/41/80/2 113/72 4
(0) Non-transfused 163 (125/38) 60.3 ≤12, 12% 43/108/9/3 85/33/41/4 121/42
Ghosh [16] (2004) 1996–2003 (UK) 23.2# Transfused 120 (73/47) 72 – 62/58/0/0 29/66/27/0 All Pr 5
(−) Non-transfused 209 (99/110) 69 – 83/126/0/0 53/85/58/0 All Pr
Berardi [17] (2005) 1996–2001 (Italy) 27 Transfused 97 (−) – – – – – 4
(−) Non-transfused 342 (−) – – – – –
Peñalver [18] (2005) 1969-2000 (Spain) 208.6# Transfused 125 (120/5) 62.6 ± 9.01 – 21/89/15/0 All stage I 81/44 5
(−) Non-transfused 731 (688/43) 61.9 ± 8.95 – 199/466/66/0 All stage I 584/147
Chen [19] (2007) 1993-2002 (China) – Transfused 135 (110/25) 58.6 ± 11.2 13.8 ± 2.1 60/55/5/15 50/27/58/0 – 5
(0) Non-transfused 145 (117/28) 59.8 ± 11.1 14.2 ± 1.4 75/52/5/13 74/26/45/0 –
Thomas [20] (2007) 1993–2002 (France) – Transfused 139 (−) – – 39/77/17/6 – All Pn 5
– Non-transfused 228 (−) – – 70/113/25/20 – All Pn
Panagopoulos [21] (2008) 1999–2005 (Greece) 27.2 Transfused 85 (74/11) 64 ± 9 11.5 ± 1.6 30/46/7/2 33/27/23/2 45/40 4

















Table 1 Summary of studies included in the meta-analysis (Continued)
Ng [22] (2012) 2001–2009 (USA) 48 Transfused 63 (31/32) 74 12.6 43/12/6/2 All stage I All Pr 6
(0) Non-transfused 298 (130/168) 67 13.5 187/69/21/21 All stage I All Pr
Cata [23] (2013) 2004–2006 (USA) 63.6 Transfused 60 (31/29) 66.2 ± 9.4 12.08 ± 1.58 – 23/16/21/0 – 6
37 Non-transfused 576 (267/309) 65.1 ± 10.5 13.43 ± 1.42 – 328/115/131/0 –
EI Enrolment interval; UK United Kingdom; FD Follow-up duration; MM Median months; M Male; F Female; PHB Preoperative hemoglobin; TS Tumor stage; Aa Adenocarcinoma; Sc Squamous cell carcinoma; Lc Large cell


















Figure 1 Forest plot showing the impact of perioperative blood transfusion on overall survival.
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Visual assessment of a funnel plot of the studies used in
the meta-analysis reporting on OS is shown in Figure 3.
Two of the studies lay outside the limits of the 95% CI,
indicating evidence of publication bias.
Discussion
Blood transfusion is life saving in many circumstances
but it also poses significant adverse effects, including in-
compatibility, transmission of viral diseases, coagulopa-
thy, and allergic reactions [1]. In addition, it confers a
significant cost and is an increasingly pressured re-
source. In 1982, Burrows and Tartter reported a higher
recurrence rate in transfused patients after colon cancer
resection as compared with matched untransfused pa-
tients [24]. Since then, numerous studies have addressed
the effect of perioperative blood transfusion on patient
survival after cancer surgery. Chung et al. [25] reviewed
20 studies that examined the effect of blood transfusion
on prognosis after resection for colorectal carcinoma
and found that transfusion was associated with an in-
creased risk of tumor recurrence and cancer-related
death. Also, in the field of hepatocellular carcinoma sur-
gery, a recent meta-analysis conducted by Liu et al. [26]Figure 2 Forest plot showing the impact of perioperative blood transcompared 22 studies that included 5635 patients and
demonstrated that perioperative blood transfusion was
associated with adverse clinical outcomes, including in-
creased deaths, recurrences and complications. For lung
cancer surgery, this subject is particularly relevant be-
cause of high transfusion rates ranging from 9.4% to
55.4%, as demonstrated in the present study. To the best
of our knowledge, our study provides the first meta-
analysis on the effect of perioperative blood transfusion
on long-term outcomes after lung cancer surgery, for it
included 18 studies with a sufficiently large sample size
(n = 5915). The results show that perioperative blood
transfusion has an unfavorable impact on prognosis in
terms of OS and RFS.
Consistent with the clinical observations, experimental
animal data indicate that blood transfusion facilitates tumor
growth [27]. The most popular hypothesis is that blood
transfusion-associated immunosuppressive alterations, such
as the decreased helper/suppressor T-lymphocyte ratio, de-
creased natural killer cell function, defective antigen pres-
entation and decreased cell-mediated immunity, might
decrease tumor surveillance and worsen the prognosis [1].
In addition, there is evidence that transfusion has a signifi-
cant impact on postoperative morbidity. In a retrospectivefusion on recurrence-free survival.
Table 2 Results of sensitivity analysis
Outcome No. of studies RR (95% CI) P value I2 (%) HG p value
Patients with stage I disease
OS 5 [6,14,18,21,22] 1.39 (1.03, 2.02) 0.02 66 0.02
RFS 5 [2,5-7,14,22] 1.51 (1.14, 2.01) 0.005 60 0.03
High-quality studies
OS 6 [6,8,13,14,22,23] 1.58 (1.19, 2.08) 0.001 61 0.02
RFS 6 [6,8,13,14,22,23] 1.52 (1.14, 2.01) 0.004 57 0.04
Studies with >200 patients
OS 12 [6,9,13-18,20-23] 1.26 (1.12, 1.41) < 0.001 66 < 0.001
RFS 7 [6,7,13,14,19,22,23] 1.41 (1.13, 1.75) 0.002 61 0.02
RR, Relative risk ratio; HG, Heterogeneity; OS, Overall survival; RFS, Recurrence-free survival.
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for thoracic malignancies, the incidence of infectious
complications was 13.7% in transfused patients and
5.6% in non-transfused patients (P =0.004) [20]. Infec-
tion induces the release of cytokines and chemokines
including tumor necrosis factor-alpha, interleukin 6,
and interleukin 8, which have been proposed as media-
tors of cancer development [28].
With respect to colorectal liver metastasis, Stephenson
et al. [29] reported that patients who received more than
11 units of blood had significantly shorter disease-free
intervals and worse survival than those who received 3–
10 units of blood after surgery. Of the included studies
in the current analysis, Pastorino, Keller, Little, Nosotti
and their colleagues noted that the number of units
transfused did not affect the survival or recurrence-free
survival [5-7,14]. In contrast, Cata et al. [23] found that
the number of units transfused was a factor associated
with worse RFS and OS. We were unable to examine
whether there was a dose-dependent effect of transfusionFigure 3 Funnel plot analysis of publication bias. The outcome was ovon survival because the stratification for the amount of
transfused blood was not always the same between these
studies.
Several weaknesses of the present study should be
taken into consideration in interpreting our results. First,
all the included studies were retrospective and are there-
fore subject to inherent biases, although the results of
pooled data of multivariate RRs are similar to the find-
ings from overall analysis. Second, funnel plot analysis
revealed the sign of publication bias, which may relate
to only published studies included. Third, significantly
heterogeneity was detected within primay outcomes.
There are considerable disparities between the studies
that might introduce heterogeneity, including variation
in the preoperative status (such as the American Society
of Anesthesiologist physical status, body mass index, co-
morbidities and hemoglobin level), disease stage, the
extent of resection and transfusion policies. In addition,
some patients received preoperative or postoperative
chemotherapy, which might have influenced the outcome.erall survival.
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over a 20-year period, improvements in operative tech-
niques and anesthesiological management as well as peri-
operative care are strongly linked to the outcome after
lung cancer surgery. In order to minimize this effect, the
RR was calculated by a random-effects model. Finally, it
has been suggested that pre-, intra-, and postoperative ad-
ministration of blood would increase the likelihood of
colorectal cancer recurrences by 50, 74 and 36%, respect-
ively [30]. Unfortunately, no study available has reported
the effect of the timing of transfusion on long-term sur-
vival or tumor recurrence after lung cancer resection.
Given a negative effect of transfusion on lung cancer
survival, both surgeons and anesthesiologists should be
more prudent in using perioperative blood transfusion.
Cata et al. [31] proposed an patient blood management
protocol that comprises three main components: (i) evalu-
ating high-risk patients and optimizing erythrocyte mass
and function for such patients; (ii) minimizing peri-
operative erythrocyte loss through blood-sparing surgical
techniques, maintenance of normothermia, intraoperative
cell salvage techniques when appropriate, use of antifibri-
nolytics when indicated, and optimized fluid therapy and
haemodynamic control; and (iii) using patient-specific
transfusion triggers to decide when administration of blood
products is warranted.
Conclusions
The current literature review suggests that perioperative
blood transfusion appears to be associated with a worse
prognosis in patients undergoing lung cancer resection,
which highlights the importance of avoiding or minimiz-
ing blood transfusion.
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